top of page
Starting August 1, 2024, Quickarrays, Inc. will be providing all products and services in place of Pantomics Inc.
SERVICES
CUSTOM TMA
ROUTINE PATHOLOGY
IHC / IMMUNOFLUORESCENCE
ISH / FISH
CONTRACTED SERVICES
PRIMARY IHC ANTIBODIES
PATHOLOGY FIELD
Hermatopathology
DETECTION SYSTEMS
ANCILLARIES
CONTROL TMA
MTU951
40 types of tumors covering all the common benign, malignant and metastatic entities originated from 27 anatomic sites. Most of them have duplicates or triplicates from different individuals with corresponding uninvolved tissues as controls with grading and TNM staging data.
Specification
Data Sheet
TNM Grading
Downloads
Price
Size
Availability
$298
1 slide
In-Stock
A | |
B | |
C | |
D | |
E | |
F | |
G | |
H | |
Human
95
95
1.5mm
4um
8
12
Paraffin
Notes:
All tissues were fixed in 10% neutral buffered formalin for 24 hours and processed using identical SOPs. Sections were picked onto Superfrost Plus or Startfrost Adhesive slides. They all have a guaranteed six month shelf-life at 4C from the date of shipment. Additional cores not listed are orientation markers and have no data. There maybe <5% core loss per slide but the core retention rate should be >90%.
Bake at 60C for 30 minutes before use. If antigen retrieving is needed, it is always a good idea to start with a protocol with weak to mild strength. Please check our TNM guide as a reference. For IHC related information on products that provide them, please contact us at info@pantomics.com for the most up-to-date information.
For research use only. Designed for IHC or ISH based protein or RNA tissue profiling in all the common types of benign and malignant tumors.
ARRAY POSITION | IMAGE | SEX | AGE | ANATOMIC SITE | PATHOLOGY | GRADE | STAGE (TNM) |
|---|---|---|---|---|---|---|---|
A01 | F | 37 | Adrenal gland | Normal, hyperplasia | |||
A02 | M | 35 | Adrenal gland | Adenoma, cortical | |||
A03 | M | 28 | Adrenal gland | Adrenocortical carcinoma | T2N0M0 | ||
A04 | M | 53 | Bladder, urinary | Normal | |||
A05 | F | 53 | Bladder, urinary | Transitional cell carcinoma | I~II | T1N0M0 | |
A06 | F | 65 | Bladder, urinary | Transitional cell carcinoma | I~II | T1N0M0 | |
A07 | F | 30 | Breast | Normal | |||
A08 | F | 40 | Breast | Fibroadenoma | |||
A09 | F | 39 | Breast | Fibroadenoma | |||
A10 | F | 58 | Breast | Invasive ductal carcinoma | II | T2N1M0 | |
A11 | F | 53 | Breast | Invasive ductal carcinoma | II | T2N0M0 | |
A12 | F | 42 | Breast | Invasive ductal carcinoma | II | T4N1M0 | |
B01 | M | 17 | Bone, tibia | Osteosarcoma | |||
B02 | M | 44 | Bone, scapula | Chondrosarcoma | |||
B03 | M | 58 | Brain, cerebellum* | Normal, cerebellum* | |||
B04 | F | 65 | Brain, cerebellum | Meningioma, fibroblastic | |||
B05 | M | 55 | Brain, cerebellum | Malignant meningioma | |||
B06 | M | 58 | Brain, cerebral cortex* | Normal cerebral cortex* | |||
B07 | F | 26 | Brain | Meningioma, fibroblastic | |||
B08 | M | 47 | Brain | Astrocytoma | II | ||
B09 | M | 53 | Esophagus | Normal | |||
B10 | F | 68 | Esophagus | Squamous cell carcinoma | I | T2N0M0 | |
B11 | M | 54 | Esophagus | Squamous cell carcinoma | II | T3N1M0 | |
B12 | F | 61 | Esophagus | Squamous cell carcinoma | III | T2N1M0 | |
C01 | M | 59 | Stomach | Normal | |||
C02 | M | 52 | Stomach | Adenocarcinoma | I | T2N0M0 | |
C03 | M | 66 | Stomach | Adenocarcinoma | II | T3N0M0 | |
C04 | M | 47 | Stomach | Adenocarcinoma | III | T3N2M0 | |
C05 | F | 40 | Intestine, small intestine | Normal | |||
C06 | F | 18 | Intestine, small intestine | Adenoma | |||
C07 | F | 57 | Intestine, small intestine | Adenocarcinoma | II | T2N0M0 | |
C08 | F | 27 | Intestine, colon | Normal | |||
C09 | M | 57 | Intestine, colon | Adenoma | |||
C10 | M | 56 | Intestine, colon | Adenocarcinoma | I | T3N0M0 | |
C11 | M | 89 | Intestine, colon | Adenocarcinoma | II | T2N0M0 | |
C12 | F | 43 | Intestine, colon | Adenocarcinoma | III | T3N0M0 | |
D01 | M | 61 | Intestine, rectum | Normal | |||
D02 | M | 40 | Intestine, rectum | Adenocarcinoma | I | T3N0M0 | |
D03 | M | 38 | Intestine, rectum | Adenocarcinoma | II | T3N1M0 | |
D04 | M | 50 | Intestine, rectum | Adenocarcinoma | III | T3N1M0 | |
D05 | F | 51 | Kidney | Normal cortex | |||
D06 | M | 40 | Kidney | Clear cell carcinoma | T1N0M0 | ||
D07 | F | 79 | Kidney | Clear cell carcinoma | T1N0M0 | ||
D08 | M | 43 | Liver | Normal | |||
D09 | M | 26 | Liver | Hepatocellular carcinoma | I | T2N0M0 | |
D10 | M | 40 | Liver | Hepatocellular carcinoma | II | T2N0M0 | |
D11 | M | 53 | Liver | Hepatocellular carcinoma | I | T2N0M0 | |
D12 | M | 41 | Liver | Hepatocellular carcinoma | III | T2N0M0 | |
E01 | M | 58 | Lung | Normal | |||
E02 | M | 59 | Lung | Squamous cell carcinoma | II | T2N2M0 | |
E03 | M | 62 | Lung | Squamous cell carcinoma | II~III | T2N0M0 | |
E04 | M | 72 | Lung | Adenocarcinoma | III | T2N2M0 | |
E05 | M | 19 | Lung | Small cell carcinoma | T3N0M0 | ||
E06 | F | 39 | Lymph node | Reactive | |||
E07 | M | 50 | Lymph node, neck | Lymphoma, Hodgkin lymphoma | |||
E08 | M | 42 | Lymph node, axillary | Lymphoma, non-Hodgkin B-cell lymphoma | |||
E09 | M | 51 | Lymph node, neck | Lymphoma, anaplastic large cell lymphoma | |||
E10 | F | 48 | Head and neck, oral cavity, hard palate | Adenocarcinoma | III~IV | ||
E11 | M | 56 | Head and neck, oral cavity, tongue | Squamous cell carcinoma | II | T2N0M0 | |
E12 | F | 48 | Head and neck, nasopharynx | Nasopharyngeal carcinoma, NPC | III | T2N0M0 | |
F01 | F | 45 | Ovary | Normal | |||
F02 | F | 55 | Ovary | Granulosa cell tumor | |||
F03 | F | 45 | Ovary | Adenocarcinoma | III | T2N0M0 | |
F04 | F | 49 | Ovary | Endometrioid adenocarcinoma | III | T1N0M0 | |
F05 | M | 35 | Pancreas | Normal | |||
F06 | F | 49 | Pancreas | Adenocarcinoma | II | T3N1M1 | |
F07 | M | 65 | Prostate | Normal, hyperplasia | |||
F08 | M | 60 | Prostate | Adenocarcinoma | II | T2N0M0 | |
F09 | M | 63 | Prostate | Adenocarcinoma | III | T3N0M0 | |
F10 | M | 38 | Head and neck, salivary gland | Normal | |||
F11 | F | 28 | Head and neck, salivary gland, parotid | Pleomorphic adenoma | |||
F12 | F | 38 | Head and neck, salivary gland | Adenoid cystic carcinoma | I~II | T1N0M0 | |
G01 | M | 50 | Skin | Normal | |||
G02 | M | 67 | Skin, trunk | Squamous cell carcinoma | II | T2N0M0 | |
G03 | M | 53 | Head and neck, nasal cavity | Melanoma | |||
G04 | M | 77 | Testis | Normal | |||
G05 | M | 30 | Testis | Seminoma | |||
G06 | M | 28 | Testis | Seminoma | |||
G07 | F | 62 | Thyroid | Normal | |||
G08 | F | 47 | Thyroid | Adenoma | |||
G09 | F | 27 | Thyroid | Adenoma | |||
G10 | F | 66 | Thyroid | Adenoma | |||
G11 | M | 16 | Thyroid | Follicular carcinoma | T3N1M0 | ||
G12 | M | 34 | Thyroid | Follicular papillary adenocarcinoma | T2N1M0 | ||
H01 | F | 41 | Uterus, cervix | Normal | |||
H02 | F | 63 | Uterus, cervix | Squamous cell carcinoma | III | T1N0M0 | |
H03 | F | 57 | Uterus, cervix | Squamous cell carcinoma | III | T1N1M0 | |
H04 | F | 50 | Uterus, endometrium | Normal | |||
H05 | F | 48 | Uterus, endometrium | Adenocarcinoma | I~II | T2N0M0 | |
H06 | F | 53 | Uterus, endometrium | Adenocarcinoma | II~III | T1N1M0 | |
H07 | M | 60 | Liver | Metastatic colon adenocarcinoma | |||
H08 | M | 69 | Lung | Metastatic cancers, from gastrointestional site? | |||
H09 | F | 34 | Lymph node | Metastatic breast invasive ductal carcinoma | |||
H10 | F | 40 | Ovary | Metastatic colon signet ring cell carcinoma | |||
H11 | M | 51 | Lymph node | Metastatic esophagus squamous cell carcinoma | |||
null |
bottom of page